Ji Wang1, Jie-Jun Cheng1, Kai-Yi Huang2, Zhi-Guo Zhuang1, Xue-Bin Zhang1, Jia-Chang Chi1, Xiao-Lan Hua1, Jian-Rong Xu3. 1. Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Pujian Rd. 160, Shanghai, 200127, China. 2. Siemens Limited China, Shanghai Branch, Zhouzhu Rd. 278, Shanghai, 201318, China. 3. Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Pujian Rd. 160, Shanghai, 200127, China. jianr_xu@163.com.
Abstract
PURPOSE: The aim of this study was to develop a quantitative measurement of perfusion reduction using color-coded digital subtraction angiography (ccDSA) to monitor intra-procedural arterial stasis during TACE. MATERIALS AND METHODS: A total number of 35 patients with hepatocellular carcinoma who had undergone TACE were enrolled into the study. Pre- and post-two-dimensional digital subtraction angiography scans were conducted with same protocol and post-processed with ccDSA prototype software. Time-contrast-intensity (CI[t]) curve was obtained by region-of-interest (ROI) measurement on the generated ccDSA image. Quantitative 2D perfusion parameters time to peak, area under the curve (AUC), maximum upslope, and contrast intensity peak (CI-Peak) derived from the ROI-based CI[t] curve for pre- and post-TACE were evaluated to assess the reduction of antegrade blood flow and tumor blush. Relationships between 2D perfusion parameters, subjective angiographic chemoembolization endpoint (SACE) scale, and clinical outcomes were analyzed. RESULTS: Area normalized AUC and CI-Peak revealed significant reduction after the TACE (P < 0.0001). AUCnorm decreased from pre-procedure of 0.867 ± 0.242 to 0.421 ± 0.171 (P < 0.001) after completion of TACE. CI-Peaknorm was 0.739 ± 0.221 before TACE and 0.421 ± 0.174 (P < 0.001) after TACE. Tumor blood supply time slowed down obviously after embolization. A perfusion reduction either from AUCnorm or CI-Peaknorm ranging from 30% to 40% was associated with SACE level III and a reduction ranging from 60% to 70% was equivalent to SACE level IV. For intermediate reduction (SACE level III), better tumor response was found after TACE rather than a higher reduction (SACE level IV). CONCLUSION: ccDSA application provides an objective approach to quantify the perfusion reduction and subjectively evaluate the arterial stasis of antegrade blood flow and tumor blush caused by TACE.
PURPOSE: The aim of this study was to develop a quantitative measurement of perfusion reduction using color-coded digital subtraction angiography (ccDSA) to monitor intra-procedural arterial stasis during TACE. MATERIALS AND METHODS: A total number of 35 patients with hepatocellular carcinoma who had undergone TACE were enrolled into the study. Pre- and post-two-dimensional digital subtraction angiography scans were conducted with same protocol and post-processed with ccDSA prototype software. Time-contrast-intensity (CI[t]) curve was obtained by region-of-interest (ROI) measurement on the generated ccDSA image. Quantitative 2D perfusion parameters time to peak, area under the curve (AUC), maximum upslope, and contrast intensity peak (CI-Peak) derived from the ROI-based CI[t] curve for pre- and post-TACE were evaluated to assess the reduction of antegrade blood flow and tumor blush. Relationships between 2D perfusion parameters, subjective angiographic chemoembolization endpoint (SACE) scale, and clinical outcomes were analyzed. RESULTS: Area normalized AUC and CI-Peak revealed significant reduction after the TACE (P < 0.0001). AUCnorm decreased from pre-procedure of 0.867 ± 0.242 to 0.421 ± 0.171 (P < 0.001) after completion of TACE. CI-Peaknorm was 0.739 ± 0.221 before TACE and 0.421 ± 0.174 (P < 0.001) after TACE. Tumor blood supply time slowed down obviously after embolization. A perfusion reduction either from AUCnorm or CI-Peaknorm ranging from 30% to 40% was associated with SACE level III and a reduction ranging from 60% to 70% was equivalent to SACE level IV. For intermediate reduction (SACE level III), better tumor response was found after TACE rather than a higher reduction (SACE level IV). CONCLUSION: ccDSA application provides an objective approach to quantify the perfusion reduction and subjectively evaluate the arterial stasis of antegrade blood flow and tumor blush caused by TACE.
Authors: Sabine K Maschke; Julius Renne; Thomas Werncke; Karen M Olsson; Marius M Hoeper; Frank K Wacker; Bernhard C Meyer; Jan B Hinrichs Journal: Eur Radiol Date: 2017-03-30 Impact factor: 5.315
Authors: Lena S Becker; Klaus Stahl; Timo C Meine; Christian von Falck; Bernhard C Meyer; Cornelia L A Dewald; Nina Rittgerodt; Markus Busch; Sascha David; Frank Wacker; Jan B Hinrichs Journal: Abdom Radiol (NY) Date: 2020-10
Authors: Timo C Meine; Sabine K Maschke; Martha M Kirstein; Elmar Jaeckel; Becker S Lena; Thomas Werncke; Cornelia L A Dewald; Frank K Wacker; Bernhard C Meyer; Jan B Hinrichs Journal: Medicine (Baltimore) Date: 2021-02-19 Impact factor: 1.817
Authors: Carson Hoffman; Sarvesh Periyasamy; Colin Longhurst; Rafael Medero; Alejandro Roldan-Alzate; Michael A Speidel; Paul F Laeseke Journal: CVIR Endovasc Date: 2021-01-07